AMRA Medical, as part of a collaborative effort composed of researchers from the University of Glasgow, University Hospitals ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

First, he landed his role in "Modern Family," a critically acclaimed ABC sitcom that went on for 11 seasons and catapulted ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Emmy Award-winning actor Eric Stonestreet, known for his portrayal of Cameron Tucker on ABC’s hit sitcom Modern Family, has revealed his private health journey with type 2 diabetes and how medication ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

Modern Family’ alum Eric Stonestreet opened up to PEOPLE about living with type 2 diabetes and being unable to get a grasp on ...

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.

Eli Lilly on Thursday reported first-quarter profit above Wall Street estimates, helped by strong sales of its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro. On an adjusted basis ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Eli Lilly reported a strong revenue jump driven by the blockbuster performance of its weight loss and diabetes drugs, ...

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.